Assignee
PROLYNX LLC
US·13 granted patents·13 pending applications·27 citations·filing 2012–2025
Top patents by PatentIndex Score
26 records- 0195US11179470B2Hydrogels with biodegradable crosslinkingPROLYNX LLC·Filed 2019·Granted Nov 23, 2021·7 cites·11 claims
- 0292US10398779B2Hydrogels with biodegradable crosslinkingPROLYNX LLC·Filed 2017·Granted Sep 3, 2019·4 cites·1 claims
- 0389US11181803B2Hydrogels with biodegradable crosslinkingPROLYNX LLC·Filed 2019·Granted Nov 23, 2021·2 cites·6 claims
- 0488US9387254B2Prodrugs and drug-macromolecule conjugates having controlled drug release ratesPROLYNX LLC·Filed 2014·Granted Jul 12, 2016·9 cites·7 claims
- 0586US11454861B2Hydrogels with biodegradable crosslinkingPROLYNX LLC·Filed 2019·Granted Sep 27, 2022·2 cites·7 claims
- 0684US12478680B2Hydrogels with biodegradable crosslinkingPROLYNX LLC·Filed 2022·Granted Nov 25, 2025·0 cites·16 claims
- 0776US2024082436A1Synergistic cancer treatmentPROLYNX LLC·Filed 2023·Application pending·0 cites
- 0875US2023321286A1Protocol for minimizing toxicity of combination dosages and imaging agent for verificationPROLYNX LLC·Filed 2023·Application pending·0 cites
- 0974US10016411B2Slow-release conjugates of SN-38PROLYNX LLC·Filed 2014·Granted Jul 10, 2018·2 cites·4 claims
- 1073US10342792B2Slow-release conjugates of SN-38PROLYNX LLC·Filed 2018·Granted Jul 9, 2019·1 cites·9 claims
- 1170US11730836B2Synergistic cancer treatmentPROLYNX LLC·Filed 2019·Granted Aug 22, 2023·0 cites·10 claims
- 1266US2026007768A1Conjugation linkersPROLYNX LLC·Filed 2025·Application pending·0 cites
- 1364US2026041680A1Methods of treating cancer with long-acting topoisomerase i inhibitorPROLYNX LLC·Filed 2023·Application pending·0 cites
- 1462US2026034120A1Treating cancer with long-acting topoisomerase i inhibitorPROLYNX LLC·Filed 2023·Application pending·0 cites
- 1561US12364771B2Conjugation linkersPROLYNX LLC·Filed 2020·Granted Jul 22, 2025·0 cites·11 claims
- 1658US10086049B2Conjugates of somatostatin analoguesPROLYNX LLC·Filed 2014·Granted Oct 2, 2018·0 cites·1 claims
- 1757US2024181397A1High-throughput microemulsification membranePROLYNX LLC·Filed 2022·Application pending·0 cites
- 1856US2024041982A1Extended release hydrogel conjugates of c-natriuretic peptidesPROLYNX LLC·Filed 2021·Application pending·0 cites
- 1952US12472261B2Conjugated inhibitors of DNA damage responsePROLYNX LLC·Filed 2020·Granted Nov 18, 2025·0 cites·16 claims
- 2052US2022265873A1Steam sterilization of hydrogels crosslinked by beta-eliminative linkersPROLYNX LLC·Filed 2020·Application pending·0 cites
- 2152US2022193253A1Slow-release cytokine conjugatesPROLYNX LLC·Filed 2020·Application pending·0 cites
- 2251US10413594B2Conjugates of somatostatin analoguesPROLYNX LLC·Filed 2018·Granted Sep 17, 2019·0 cites·5 claims
- 2351US2025312498A1Protocol for minimizing toxicity of combination dosages and imaging agent for verificationPROLYNX LLC·Filed 2025·Application pending·0 cites
- 2448US2015352246A1Sealants having controlled degrationPROLYNX LLC·Filed 2014·Application pending·0 cites
- 2547US2014256626A1Peg conjugates of exenatidePROLYNX LLC·Filed 2012·Application pending·0 cites
- 2638US2020164083A1Extended release conjugates of exenatide analogsPROLYNX LLC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when PROLYNX LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →